AI clinical trial matching Market Outlook 2026–2033: Growth Drivers, Key Companies, Strategic Developments & Adoption Forecast — A Meticulous Next™ Foresight Brief

This Meticulous Next™ brief examines AI clinical trial matching, software that reads patient records and trial protocols and identifies the patients who meet the eligibility criteria, so that sites and sponsors enrol faster. It tests how fast language models move from research benchmarks into routine screening at hospitals, sponsors and contract research organisations, and which participants capture value among matching vendors, clinical research platforms, record vendors, cancer centres and regulators.

The problem is large. A 2023 study from the US National Institutes of Health, as reported by Fierce Biotech, found that up to 85% of clinical trials fail to recruit enough patients, despite roughly USD 1.9 billion spent on recruitment each year. The conclusion is that recruitment delay is a cost that sponsors already pay, and a tool that shortens screening has a defined budget to draw on.

The strongest published evidence comes from TrialGPT, a language model framework from the National Library of Medicine reported in Nature Communications in November 2024. On 183 synthetic patients and more than 75,000 patient and trial annotations, it recalled more than 90% of relevant trials using less than 6% of the initial collection, and its criterion level accuracy of 87.3% compared with 88.7% to 90.0% for experts. The conclusion is that language models read eligibility criteria at close to expert level, and the practical question is performance on real records.

Speed gains are promising but based on a small test. In a user study of two annotators reviewing six patient summaries against six oncology trials, screening time fell by 42.6% with no significant loss of accuracy, and the most common error, 30.7% of errors, was concluding that information was insufficient to judge eligibility. The conclusion is that the main limit is missing information in records, not reasoning, which makes record access and data quality the buyer concern.

Testing in clinical settings is under way, with the NIH team evaluating TrialGPT in real settings under a 2024 Director Challenge Innovation Award, and Tempus presented data in October 2026 showing that AI enabled pre-screening can help identify patients with advanced non-small cell lung cancer for biomarker testing, a step that comes before trial matching. The conclusion is that the first commercial use is in oncology, where eligibility depends on biomarkers, and vendors with linked clinical and molecular data hold the advantage.

The brief treats AI clinical trial matching as an accelerating category with a seven year horizon to 2033. It identifies which applications, regions and operators scale first and what each means for matching vendors, clinical research platforms, record vendors, hospitals and sponsors. It is a focused 98-page decision brief that presents an indicative trajectory rather than a segmented market model.

AI clinical trial matching compares the eligibility criteria of a trial protocol with a patient record and predicts whether the patient qualifies, with an explanation for each criterion.

Language model frameworks such as TrialGPT retrieve candidate trials from a large registry, judge each criterion and rank trials for the patient, with a clinician confirming the result.

Platforms work from the patient side, through search tools, or from the site and sponsor side, by screening records and referring patients.

Uses are oncology and rare disease trials with narrow criteria, site selection and feasibility, and screening for biomarker testing.

The limits are missing information in records, privacy and data sharing limits, integration with site workflows, and limited evidence in real settings. The period turns on whether real world results show faster enrolment at acceptable cost.

The AI clinical trial matching market, covering software, platforms and services that screen patient records against trial protocols to identify and refer eligible patients, is valued at USD 0.3–0.5 billion in 2026 and is projected to reach USD 1.69–2.81 billion by 2033, at a CAGR of 28%.

The 2026 base rests on software, platforms and services bought by sponsors, contract research organisations, hospitals and cancer centres to identify and refer eligible patients. Growth then follows real world evidence, integration with record systems and extension beyond oncology.

The forecast is sensitive to access to records, evidence of faster enrolment and sponsor budgets. Regionally, North America leads on data access and sponsor spending, Europe on public research programmes and privacy rules, and Asia-Pacific on hospital networks and trial volumes.

Scenarios.

The base case assumes real world pilots confirm faster screening and record vendors embed matching, giving the inflection in 2030. An accelerated case assumes strong enrolment gains and broad sponsor adoption, bringing the inflection to 2029 and lifting the 2033 value to the top of the range. A delayed case assumes data access and privacy limits slow deployment, holding growth at the bottom of the range.

Growth drivers

• Recruitment failures and delays.
• Language model accuracy on eligibility criteria.
• Sponsor and contract research organisation demand.
• Precision oncology trials with narrow criteria.

Enablers

• Electronic record and registry data access.
• Public research programmes and open tools.
• Sponsor, site and vendor partnerships.
• Venture and strategic funding.

Restraints and barriers

• Missing information in records.
• Privacy and data sharing limits.
• Integration with site workflows.
• Limited evidence in real clinical settings.

The direction of AI clinical trial matching is set by recruitment delays and cost in trials, privacy, consent and regulation, language models and record access, partnering among sponsors, sites and technology vendors, and the cost of each record screened.

The key participants in AI clinical trial matching include Tempus AI, Inc., Paradigm Health, Inc., TriNetX, LLC, Dassault Systèmes SE, Veeva Systems Inc., IQVIA Holdings Inc., ICON plc, Thermo Fisher Scientific Inc., Fortrea Holdings Inc., Medpace Holdings, Inc., Oracle Corporation, Epic Systems Corporation, F. Hoffmann-La Roche Ltd, Syneos Health, Inc., BEKhealth Corporation, SubjectWell, Inc., Datavant, Inc., Lokavant, Inc., Microsoft Corporation, Alphabet Inc., National Library of Medicine, National Institutes of Health, National Cancer Institute, University of Illinois Urbana-Champaign, University of Maryland, American Society of Clinical Oncology, Mayo Clinic, MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, Cleveland Clinic, Mass General Brigham, Duke University, U.S. Food and Drug Administration, European Medicines Agency, Medicines and Healthcare products Regulatory Agency, European Commission, Pharmaceuticals and Medical Devices Agency, National Medical Products Administration, International Council for Harmonisation and TransCelerate BioPharma Inc.

The brief profiles representative participants in each archetype and assesses which are positioned to lead as AI clinical trial matching matures.

Tempus AI, TriNetX, Paradigm Health, BEKhealth, SubjectWell and Lokavant lead among dedicated matching and recruitment vendors, IQVIA, ICON, Thermo Fisher Scientific, Fortrea, Medpace and Syneos Health run trials at scale, and Veeva Systems and Dassault Systèmes supply clinical research platforms. Epic Systems and Oracle control the records that matching reads. Competitive intensity is moderate in 2026 and rises as sponsors consolidate vendors.

Where value migrates.

In 2026 value sits with vendors that hold linked clinical and molecular data and oncology reach, because sponsors pay for patients found, not for software alone. By 2030 it moves toward clinical research platforms and record vendors that embed screening, because sites will not run separate tools for each trial. By 2033 it settles in automated pre-screening inside the record. Margins hold for vendors with data and sponsor reach and narrow for stand-alone matching tools that depend on others for records.

The signals converge on benchmark accuracy and first use in oncology. A framework reached 87.3% criterion level accuracy against 88.7% to 90.0% for experts, a pilot cut screening time by 42.6%, and AI pre-screening data in lung cancer were presented in October 2026. Each signal supports growth, and missing information in records, privacy limits and thin real world evidence limit the pace.

Structural limits show where progress could slow: missing information in records, privacy and data sharing limits, integration with site workflows, and limited evidence in real clinical settings. The brief therefore tracks four indicators: real world pilot results, sponsor and site deployments, record vendor integration, and patients screened.

Oncology and biomarker driven trials first, then rare disease and other specialties, then broad pre-screening at the point of care are the expected order of adoption.